Different Name, Same Contamination, Recall Problems For US Homeopathic Nasal Spray Firm

Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.

• Source: Shutterstock/Citeline

A California firm changed the name of its homeopathic nasal spray but little else since the Food and Drug Administration warned it about microbial contamination in 2022. The agency says Green Pharmaceuticals Inc. is ignoring requests for a recall of its OTC product.

Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” may have microbial contamination and shouldn’t be used, the FDA says...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Compliance

More from Policy & Regulation

UK FSA Issues New Guidelines For CBD And THC Max Levels

 
• By 

Based on advice from its advisory committees, the UK's Food Standards Agency is encouraging businesses to meet an acceptable daily intake of 10mg CBD per day and a safe upper limit of 0.07mg THC per day.

US FDA Has Lists To Assure Progress On Supplement Sector Regulations, NDIN Guidance

 

The agency says items on its Human Foods Program’s proposed agenda for guidance “to complete during 2025” include identity and safety information for NDI notifications. Its announcement also links to document about a separate key industry question, a rulemaking which would recognize NAC as a lawful

Portfolios In Large US Food Industry Merger Cleared By FTC Include Nutritional Supplements

 

FTC decision, says Bureau of Competition director Daniel Guarnera, influenced by both companies marketing different lines in different countries, limiting the number of similar products in the same categories the combined firm would offer.